Skip to content

News

Veliparib Trial Fails to Improve Outcomes in Ovarian Cancer

Veliparib Trial Fails to Improve Outcomes in Ovarian Cancer

(January 26, 2015) Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment with cyclophosphamide alone, according to a phase II study evaluating patients with high-grade serous ovarian cancer, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers. The research was … Continued

BRCA1/2 Mutations and 10 year Survival in Ovarian Cancer

BRCA1/2 Mutations and 10 year Survival in Ovarian Cancer

(January 22, 2015) In a study published in Clinical Cancer Research, researchers analyzed the effect of germline mutations in BRCA1 and BRCA2 on mortality in ovarian cancer patients up to ten years after diagnosis. The researchers found that BRCA1/2 mutations are associated with better short-term survival, but this advantage decreases over time and, in BRCA1 … Continued

Ovarian Cancer Will Continue to be Sequenced After The Canc...

Ovarian Cancer Will Continue to be Sequenced After The Cancer Genome Atlas Ends

The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end. The National Cancer Institute (NCI) has announced that it will continue to intensively sequence tumors in three cancers, ovarian, colorectal and lung adenocarcinoma, with an expanded scope that incorporates detailed clinical information about the patient’s … Continued

Palliative Care Consultation Improves Symptoms in Gynecolog...

Palliative Care Consultation Improves Symptoms in Gynecologic Cancer Patients

A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation. Palliative care (or treatment) relieves symptoms such as pain, and reduces the suffering caused by cancer. Its main purpose is to keep the best quality of life … Continued

FDA Approves Olaparib for Ovarian Cancer

FDA Approves Olaparib for Ovarian Cancer

(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly ADP-ribose polymerase) inhibitor class. The FDA also approved Myriad Genetics’ BRACAnalysis CDx test to determine patients’ BRCA status as a companion diagnostic for determining whether … Continued

Under the Microscope: OCRF’s 2014 Research Progress R...

Under the Microscope: OCRF’s 2014 Research Progress Report

(12/14/14) | In 2014, with your generous support OCRF grantees made significant advances in the fight against ovarian cancer, including: Thank you for supporting our mission to fund scientific research that will lead to more effective identification, treatment, and ultimately a cure for this terrible disease.

OCRF Research Shows Targeting microRNA May Benefit Some Ova...

OCRF Research Shows Targeting microRNA May Benefit Some Ovarian Cancer Patients

(December 10, 2014) OCRF Ann Schreiber Mentored Investigator Award Grantee, Pradeep Chaluvally-Raghavan, Ph.D., and other researchers at The University of Texas MD Anderson Cancer Center believe they may have found a molecule-based approach to halting the destructive nature of a genetic misfire called the 3q26.2 amplicon.  The research was funded in part by a grant … Continued

Population Screening for BRCA Mutations in Ashkenazi Jewish...

Population Screening for BRCA Mutations in Ashkenazi Jewish Women is Cost-Effective

Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. A new study published in the Journal of the National Cancer Institute compared the cost-effectiveness of population-based BRCA testing with the standard FH-based approach in Ashkenazi Jewish (AJ) women. The study found that population-based … Continued

FDA Approves Genentech's Avastin Plus Chemotherapy to ...

FDA Approves Genentech's Avastin Plus Chemotherapy to Treat Women With Platinum-Resistant Recurrent Ovarian Cancer

Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. The approval was based on results from a study that showed Avastin plus chemotherapy reduced the risk of disease worsening or … Continued

Bevacizumab Plus Fosbretabulin Improves Progression-Free Su...

Bevacizumab Plus Fosbretabulin Improves Progression-Free Survival in Ovarian Cancer Patients

The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society. A study found significant improvement in progression-free survival among patients treated with … Continued

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group. Analysts said oncologists expect the drug to have little or … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.